DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Atomoxetine for ATS and Opioid Dependence During Buprenorphine Maintenance Treatment in Malaysia

Information source: Yale University
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Opiate Dependence; Stimulant Dependence

Intervention: Atomoxetine (Drug)

Phase: Phase 2

Status: Completed

Sponsored by: Yale University

Official(s) and/or principal investigator(s):
Richard S Schottenfled, M.D., Principal Investigator, Affiliation: Yale University
Vicknasingam B Kasinather, Ph.D., Principal Investigator, Affiliation: Univerisiti Sains Malaysia

Summary

To evaluate the tolerability, acceptability and potential effect size of the efficacy of 4 months of atomoxetine treatment for patients with co-occurring ATS and heroin dependence (COATS) receiving buprenorphine maintenance treatment (BMT) and educational drug and HIV risk reduction counseling (EDRC).

Clinical Details

Official title: Atomoxetine for ATS and Opioid Dependence During Buprenorphine Maintenance Treatment in Malaysia

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Primary outcome: ATS (Amphetamine-type stimulant) Use

Secondary outcome:

Retention

HIV Risks

Functional status

Detailed description: The Specific Aims of the proposed study are: 1. To evaluate the tolerability, acceptability and potential effect size of the efficacy of 4 months of atomoxetine treatment for patients with co-occurring ATS and heroin dependence (COATS) receiving buprenorphine maintenance treatment (BMT) and educational drug and HIV risk reduction counseling (EDRC). 2. To better characterize patients with co-occurring ATS and heroin dependence (with regard to disturbances of mood, impulse control, executive functioning and patterns of drug use during MMT) and to evaluate the effects of atomoxetine on mood, impulsivity, and executive functioning (including attention, concentration, memory, and decision-making characteristics). 3. To provide training in drug abuse treatment, HIV prevention and treatment, and drug abuse clinical research to drug abuse clinical researchers and clinicians in Kota Bharu, Malaysia.

Eligibility

Minimum age: 18 Years. Maximum age: 65 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Meet Opioid and Amphetamine-type stimulant (ATS)dependence, as assessed by the

Structured Clinical Interview for Diagnostic and Statistical Manual (DSM-IV) (SCID) and documented by opioid-positive and ATS positive urine tests.

- Report at least 2 or more days per week of ATS use over the past month.

Exclusion Criteria:

- Hypersensitivity to atomoxetine;

- Current use of a monoamine oxidase inhibitor (MAOI) or use within the preceding 2

weeks;

- Suffer from narrow angle glaucoma; pheochromocytoma; severe cardiovascular disorder;

liver enzymes greater than 3 times the upper limit of normal; liver failure or acute hepatitis;

- Pregnancy or breast feeding;

- Current suicide or homicide risk;

- Current psychotic disorder or major depression;

- Inability to understand the protocol or assessment questions.

- A physician reviews the results of all baseline assessments and laboratory and other

medical tests (CBC, chemistries, liver enzymes, HIV and Hepatitis B and C, EKG, chest x-ray), takes a medical history, and performs a physical examination in order to confirm the patient's eligibility for the study.

Locations and Contacts

Universiti Sains Malaysia, Kota Bharu, Malaysia
Additional Information

Starting date: May 2013
Last updated: January 21, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017